On April 24, 2024 Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, reported an upcoming poster presentation at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting taking place May 31-June 4 in Chicago (Press release, Mural Oncology, APR 24, 2024, View Source [SID1234642291]). The details are as follows:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Recommended phase 2 dose (RP2D) of nemvaleukin alfa in patients (pts) with advanced solid tumors treated with less frequent intravenous (IV) dosing (ARTISTRY-3)
Session: Developmental Therapeutics – Immunotherapy
Date and time: June 1, 2024, 9 a.m. CDT
Abstract #: 2587
Speaker/lead author: Sarina Piha-Paul, MD
The poster will be available at muraloncology.com/publications following the presentation.
About Nemvaleukin
Nemvaleukin alfa (nemvaleukin) is a novel, engineered cytokine designed to leverage antitumor effects of the IL-2 pathway while mitigating its hallmark toxicities that limit its use. Nemvaleukin selectively binds to the intermediate-affinity IL-2 receptor (IL-2R) and is sterically occluded from binding to the high-affinity IL-2R. Because of this molecular design, nemvaleukin treatment leads to preferential expansion of antitumor CD8+ T cells and natural killer cells, with minimal expansion of immunosuppressive regulatory T cells. Nemvaleukin is currently being evaluated in two potentially registrational trials in platinum resistant ovarian cancer and mucosal melanoma.
A newly recommended phase 2 dose of nemvaleukin (infusions on days 1 and 8 per three-week dosing cycle) will be explored in monotherapy and in combination with pembrolizumab in patients with cutaneous melanoma as part of the ARTISTRY-6 trial.